Clinical trials: Transfusions
Lymphoproliferative Disorders
Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
In many countries, numerous steps are taken to minimize the risk of infection from transfused blood products. Typically, blood banking organisations will screen for an array of infectious pathogens as part of their quality…
- Trial name
- TREASuRE (NCT02505789)
- Testing
- Determining the source of EBV in severe EBV infections
- Where
- 3 sites in Canada
- Volunteers
- 324 people
- Sponsor
- St. Justine's Hospital
Beta Thalassemia Intermedia
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.
- Trial name
- NCT04059406
- Testing
- sapablursen
- Where
- 19 sites in Australia, Greece and 3 more
- Volunteers
- 29 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Traumatic Head Injury, Intracranial Hemmorhage
Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury
The objective of this study is to determine if the administration of platelets will improve outcome in patients with ICH who are being treated with either aspirin, a thienopyridine (ticlodipine, clopidogrel, prasugrel) or a…
- Conditions
- Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
- Trial name
- PUNCH (NCT01810276)
- Testing
- Saline, Platelets
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Christiana Care Health Services
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
This is an open label, single arm, and multicenter study. The study will include the following phases. A screening phase which lasts for 4 weeks to determine patient eligibility.
- Trial name
- NCT01948817
- Testing
- Deferasirox
- Sponsor
- Novartis Pharmaceuticals
Transfusion Dependent Beta Thalassemia
Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia
Beta thalassemia Major (BTM) is the most common hemoglobinopathy caused by mutations in the beta-globin gene . Worldwide, approximately 80 million people carry thalassemia gene mutation.
- Trial name
- Thal-H (NCT07292259)
- Testing
- ADDITION OF THALIDOMIDE AND HYDROXYUREA
- Where
- 9 sites in Pakistan
- Volunteers
- 100 people
- Sponsor
- Pakistan Blood and Marrow Transplant (PBMT) Group
General Surgery, Blood Loss, Surgical
Intraoperative Estimated Blood Loss, Blood Transfusion, and Postoperative Clinical Outcomes in Patients Undergoing Non Cardiac Surgery, Siriraj Hospital
After review literature, Siriraj hospital has not unanimous protocol to guide proper preoperative anemia and blood transfusion. This retrospective study will review non-cardiac surgery cases and collect data such as demographic…
- Trial name
- NCT05430659
- Testing
- observational study
- Where
- Thailand
- Volunteers
- 1,268 people
- Sponsor
- Siriraj Hospital
Blood Loss, Surgical, Pediatric Heart Surgery
Effects of Intraoperative Blood and Blood Product Consumption on Postoperative Results in Pediatric Cardiac Surgery
Blood products and intravenous fluids are frequently used in the treatment of children who have undergone cardiac surgery in order to maintain hemodynamic stability.
- Trial name
- NCT03291769
- Where
- Turkey (Türkiye)
- Volunteers
- 83 people
- Sponsor
- Cukurova University
Non-transfusion Dependent Thalassemia
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
CICL670A2209: This study will evaluate the safety and efficacy of deferasirox in non-transfusion dependent thalassemia patients with iron overload.
- Trial name
- THALASSA (NCT00873041)
- Testing
- deferasirox
- Where
- 21 sites in United States, Greece and 7 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Placenta Accreta Spectrum
Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion
Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion.
- Trial name
- NCT04927988
- Testing
- Ringer's Lactated
- Where
- China
- Sponsor
- Maternal and Child Health Hospital of Foshan
Anemia of Prematurity
Autologous Cord Blood Transfusion in Preterm Infants
The purpose of this study is to investigate the efficacy and safety of autologous cord blood transfusions in very-low-birth-weight premature infants, and to evaluate the developmental outcomes of the infants who received…
- Trial name
- NCT02101086
- Testing
- Blood transfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Ankara University
Pulmonary Hypertension, Sickle Cell Disease
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension
Pulmonary hypertension, a complication associated with an increased risk of death, is common in patients with sickle cell disease.
- Trial name
- NCT00850369
- Testing
- RBC transfusion
- Sponsor
- University of North Carolina, Chapel Hill
Kidney Injury
Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study
One of the major complications of heart surgery is kidney injury, which occurs in up to 30% of patients and is associated with poor outcomes including death.
- Trial name
- NCT00861822
- Testing
- Advanced red blood cell transfusion
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Blood Loss, Surgical
Intraoperative Volume Management and QT Interval
QT interval changes is measured during all phases of the operation. The protocol is focusing at intraoperative bleeding events and is also observing QT interval changes during anesthetic and operative procedures.
- Trial name
- NCT02441751
- Testing
- intra-operative blood loss
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Technische Universität Dresden
Covid19, Convalescence
Convalescent Plasma Therapy in Severe COVID-19 Infection
As of March 18, 2020, COVID-19 cases were reported in approximately 195 countries. No specific therapeutic agents or vaccines for COVID-19 are available.
- Trial name
- NCT04403477
- Testing
- Convalescent plasma
- Where
- Bangladesh
- Volunteers
- 20 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Anemia
Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO
The investigators seek to determine whether providing inhaled nitric oxide (iNO; a vasodilator) will improve the delivery of oxygen to the brain, kidney and intestines of preterm neonates during and after the subject receives a…
- Trial name
- iNO-TRAGI (NCT02851472)
- Testing
- Inhaled Nitric Oxide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
Sickle Cell Disease
Transfusion Alternatives Pre-operatively in Sickle Cell Disease (TAPS)
TAPS is a sequential trial which aims to investigate whether the administration of a blood transfusion pre-operatively to patients with sickle cell disease (HB SS or Hb SB0 thal)having low or medium risk elective surgery…
- Trial name
- TAPS (NCT00512577)
- Testing
- Red blood cell transfusion
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- NHS Blood and Transplant
Trauma, Blood Transfusion Complication
UltraMTP in Adult Trauma Patients Undergoing Surgery Within 24 Hours: Effects on Mortality and Clinical Outcomes
The purpose of this study is to determine the effects of ultraMTP (>/=30 units pRBC within 24 hours) in trauma patients on mortality and secondary outcomes.
- Conditions
- Trauma, Blood Transfusion Complication, Death
- Trial name
- NCT04866953
- Testing
- Blood transfusion
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- University of Southern California
Acquired Factor XIII Deficiency Disease
Impact of Acquired FXIII Deficiency on Morbidity and Mortality
Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality
- Trial name
- NCT04416594
- Testing
- Data collection
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Patricia Duque González
β -Thalassemia
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood…
- Trial name
- NCT06302491
- Testing
- AND017 capsules
- Where
- 5 sites in China
- Volunteers
- 64 people
- Sponsor
- Kind Pharmaceuticals LLC
Transfusions, Cystectomy
Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions.
What influence does robot-assisted surgical treatment in the sense of a radical cystectomy and possibly bladder reconstruction have on blood loss, pain and transfusion requirements? We intend to conduct a corresponding…
- Conditions
- Transfusions, Cystectomy, Blood Loss Requiring Transfusion, Anaemia
- Trial name
- NCT07008261
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Goethe University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.